[Menu] [Previous] [Next]

TUTORIAL: Clinical PET Cases - Oncology - Credits and References

 Use the "Menu" button to jump to the Let's Play PET Main Menu or click on the Next (right arrowhead) and Previous (left arrowhead) buttons to proceed sequentially through the topics and tutorials. Or, you can return to the Department of Molecular and Medical Pharmacology's Home Page.

Credits

 Material for this section was kindly provided by:

Carl Hoh, M.D.
Dept. of Radiological Sciences and
Dept. of Molecular and Medical Pharmacology
UCLA School of Medicine

Yong Choi, Ph.D.
Dept. of Radiology
University of Pittsburgh School of Medicine

Randall Hawkins, M.D., Ph.D.
Nuclear Medicine Division
UCSF School of Medicine

References

  1. Adler, L, Blair, H, Makley, J, et al: Noninvasive grading of musculoskeletal tumor using PET. J Nucl Med, 32:1508-1512, 1991.

  2. Bailet, JW, Abemayor, E, Jabour, BA, Hawkins, RA, Hoh, CK, Ward, PH. Positron emission tomography: A new precise modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope, 102:281-288, 1992.

  3. Bakir MA; Eccles SA; Babich JW; Aftab N; Styles JM; Dean CJ; Ott RJ. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med, 1992, 33:2154-60.

  4. Beaney, R. Positron emission tomography in the study of human tumors. Sem Nucl Med, 14:324-341, 1984.

  5. Bergstrom, M. Positron emission tomography in tumor diagnosis and treatment follow-up. Acta Oncologica, 32: 183-188, 1993.

  6. Blau, M, Ganatra, R, Bender, M. 18F-Fluoride for bone imaging. Semin Nucl Med, 2:31-37, 1972.

  7. Borbely, K, Fulham, MJ, Brooks, RA, Di Chiro, G: PET-fluorodeoxyglucose of cranial and spinal neuromas. J Nucl Med, 33:1931-1934, 1992.

  8. Cherry S, Carnochan P, Babich JW, Serafini F, Rowell N, Watson I. Quantitative in vivo measurements of tumor perfusion using rubidium-81 and positron emission tomography. J Nucl Med, 1990, 31:1307-15.

  9. Coleman, RE, Hoffman, JM, Hanson, MW, Sostman, HD, Schold, SC: Clinical application of PET for the evaluation of brain tumors. J Nucl Med, 32:616-622, 1991.

  10. Dahlbom, M, Hoffman, EJ, Hoh, CK, Schiepers, C, Rosenqvist, G, Hawkins, RA, Phelps, ME. Evaluation of a positron emission tomography (PET) scanner for whole body imaging. J. Nucl. Med. 33:1191-1199, 1992.

  11. Davis, W, Boyko, O, Hoffman, J, Hanson, M, Schold, S, Burger, P, Friedman, A, Coleman, R. [F-18]2-Fluoro-2-Deoxyglucose positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. Am J Neuroradiol, 14: 515-523, 1993.

  12. DiChiro, G, DeLaPaz, RL, Brooks, RA, et al: Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology, 32:1323-1329, 1982.

  13. DiChiro, G, Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors. Invest Radiol, 22:360-371, 1987.

  14. DiChiro, G, Fulham, M: Virchow's shackles: Can PET-FDG challenge tumor histology? AJNR 14:524-527, 1993.

  15. Dimitrakopoulou, A, Strauss, L, Clorius, J, Ostertag, H, Schlag, P, Heim, M, et al: Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med, 34:1075-1081, 1993.

  16. Doyle, WK, Budinger, TF, Valk, PE, Levin, VA, Gutin, PH: Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr, 11:563-570, 1987.

  17. Eriksson, B, Bergstrom, M, Lilja, A, Ahlstrom, H, Langstrom, B, Oberg, K. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncologica, 32: 189-196, 1993.

  18. Fowler, JS, Hoffman, EJ, Larson, SM, et al: Positron emission tomography in oncology. JAMA 259:2126-2131, 1988.

  19. Haberkorn, U, Strauss, L, Kimitrakopoulou, A, et al: PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med, 32:1485-1490, 1991.

  20. Haberkorn, U, Strauss, LG, Reisser, CH. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J. Nucl. Med., 32:1548-1554, 1991.

  21. Harney JV; Wahl RL; Liebert M; Kuhl DE; Hutchins GD; Wedemeyer G; Grossman HB. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urology, 1991, 145:279-83.

  22. Hawkins RA; Choi Y; Scates S; Rege S; Hoh CK; Glaspy J; Phelps ME. An animal model for in vivo evaluation of tumor glycolytic rates with positron emission tomography. J Surg Oncol, 1993, 53:104-9.

  23. Hawkins, RA, Choi, Y, Huang, SC, Messa, C, Hoh, CK, Phelps, ME. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med, 33:339-344, 1992.

  24. Hawkins, RA, Hoh, CK, Dahlbom, M, Choi, Y, Glaspy, J, Tse, N, Slamon, D, Chen, B, Messa, C, Maddahi, J, Phelps, ME. PET cancer evaluations with FDG. J. Nucl. Med., 32:1555-1558.

  25. Hawkins, RA, Hoh, CK, Glaspy, J, Choi, Y, Dahlbom, M, Rege, S, Messa, C, Nietszche, E, Hoffman, E, Seeger, L, Maddahi, J, Phelps, ME. The role of positron emission tomography in oncology and other whole body applications. Sem Nucl Med, 22:268-284, 1992.

  26. Heiss, WD, Heindel, W, Herholz, K, Rudolf, J, Bunke, J, Jeske, J, Friedmann, G: Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors. J Nucl Med, 31:302-310, 1990.

  27. Higashi, K, Clavo, A, Wahl, R. Invitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med, 34:773-9, 1993.

  28. Hoffman, JM, Waskin, HA, Schifter, T, Hanson, MW, Gray, L, Rosenfeld, S, Coleman, RE: FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med, 34:567-575, 1993.

  29. Hwang DR; Mathias CJ; Welch MJ; McGuire AH; Kadmon D. Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl)putrescine. Int J Radiat Appl Instr B Nucl Med Biol, 1990, 17:525-32.

  30. Ishiwata K; Takahashi T; Iwata R; Tomura M; Tada M; Itoh J; Kameyama M; Ido T. Tumor diagnosis by PET: potential of seven tracers examined in five experimental tumors including an artificial metastasis model. Int J Radiat Appl Instr B Nucl Med Biol, 1992, 19:611-8.

  31. Ishiwata K; Yamaguchi K; Kameyama M; Fukuda H; Tada M; Matsuzawa T; Muraishi K; Itoh J; Kawashima K; Takahashi T. 2-Deoxy-2-[18F]fluoro-D-galactose as an in vivo tracer for imaging galactose metabolism in tumors with positron emission tomography. Int J Radiat Appl Instr B Nucl Med Biol, 1989, 16:247-54.

  32. Jabour, BA, Choi, Y, Hoh, CK, Rege, S, Soong, JC, Lufkin, RB, Hanafee, WN, Maddahi, J, Chaiken, L, Bailet, J, Phelps, ME, Hawkins, RA. PET imaging of the extracranial head and neck using 2-(18F)fluoro-2-deoxyglucose (FDG) with MRI correlation. Radiology, 186:27-35, 1993.

  33. Kern KA. [14C]deoxyglucose uptake and imaging in malignant melanoma. J Surg Res, 1991, 50:643-7.

  34. Kern, KA, Brunetti, A, Norton, JA, et al: Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med, 29:181-186, 1988.

  35. Kim, CK, Alavi, JB, Alavi, A, Reivich, M: New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol, 10:85-91, 1991.

  36. Kubota, K, Matsuzawa, T, Amemiya, A, et al., Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr, 13:1097-1098, 1989.

  37. Levivier, M, Goldman, S, Bidaut, L, Luxen, A, et al: Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 31:792-797, 1992.

  38. Lindholm, P, Minn, H, Leskinen-Kallio, S, Bergman, J, Ruotsalainen, U, Joensuu, H: Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. J Nucl Med, 34:1-6, 1993.

  39. Macke, H, Smithjones, P, Maina, T, Stolz, B, Albert, R, Bruns, C, Reist, H. New octreotide derivatives for invivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). Horm Metab Res, 27(Suppl): 12-17, 1993.

  40. Mineura, K, Yashuda, T, Kowada, M, et al: PET evaluation of histologic malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurolog Res, 8:164-168, 1986.

  41. Minn H; Paul R. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future [editorial]. Eur J Nucl Med, 1992, 19:921-4.

  42. Minn, H, Paul, R, Ahonen, A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med, 29:1521-1525, 1988.

  43. Muhr C; Bergstrom M. Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest, 1991, 14:509-28.

  44. Myers, EM, Leffall, LD. Head and neck oncology: Diagnosis, treatment and rehabilitation. Little, Brown and Company, 1991.

  45. Ogawa, T, Shishido, F, Kanno, I, Inugami, A, Fujita, H, Murakami, M, Shimosegawa, E, Ito, H, Hatazawa, J, Okudera, T, Uemura, K, Yasui, N, Mineura, K. Cerebral glioma - evaluation with methionine PET. Radiology, 186: 45-53, 1993.

  46. Ogawa, T, Uemura, K, Shishido, F, et al: Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of glioma: a PET study. J Comput Assist Tomogr, 12:290-297, 1988.

  47. Patronas, NJ, DiChiro, G, Kufta, C, et al: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg, 62:816-822, 1985.

  48. Rege, S, Hoh, C, Glaspy, J, Aberle, D, Dahlbom, M, Razavi, M, Phelps, M, Hawkins, R: Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 72:82-90, 1993.

  49. Rege, S, Chaiken, L, Hoh, C, Choi, Y, Lufkin, R, et al: Quantitation of the radiotherapy-induced change in FDG uptake in normal and malignant structures of the head and neck with PET. Radiology 1993 (in press).

  50. Rozental, JM, Levin, RL, Nickles, RJ, Dobkin, JA: Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol, 46:1302-1307, 1987.

  51. Rubin SC; Kairemo KJ; Brownell AL; Daghighian F; Federici MG; Pentlow KS; Finn RD; Lambrecht RM; Hoskins WJ; Lewis JL Jr; et al. High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies. Gynecolog Oncol, 1993, 48:61-7.

  52. Sasaki, M, Ichiya, Y, Kuwabara, Y, Otsuka, M, Fukumura, T, Kawai, Y, Koga, H, Masuda, K. Fluorine-18-Fluorodeoxyglucose positron emission tomography in Technetium-99m - Hydroxymethylenediphosphate negative bone tumors. J Nucl Med, 34: 288-290, 1993.

  53. Schifter, T, Hoffman, J, Hanson, M, Boyko, O, Beam, C, Paine, S, Schold, S, Burger, P, Coleman, R. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomog, 17:509-16, 1993.

  54. Strauss, LG, Clorius, JH, Schlag, P, et al: Recurrence of colorectal tumors: PET evaluation. Radiology, 170:329-332, 1989.

  55. Strauss, LG, Conti, PS. The application of PET in clinical oncology. J Nucl Med, 32:623-648, 1991.

  56. Tse, N, Hoh, CK, Hawkins, RA, Zinner, MJ, Dahlbom, M, Choi, Y., Maddahi, J, Brunicardi, C, Phelps, ME, Glaspy, JA. The application of positron emission tomography with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg, 216:27-34, 1992.

  57. Verhagen A; Elsinga PH; de Groot TJ; Paans AM; de Goeij CJ; Sluyser M; Vaalburg W. A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography. Canc Res, 1991, 51:1930-3.

  58. Wahl RL; Harney J; Hutchins G; Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urology, 1991, 146:1470-4.

  59. Wahl RL; Hutchins GD; Buchsbaum DJ; Liebert M; Grossman HB; Fisher S. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer, 1991, 67:1544-50.

  60. Wahl, RL, Cody, RL, Hutchins, GD, Mudgett, EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology, 179:765-770, 1991.

  61. Wahl, RL, Quint, LE, Cieslak, RD, Aisen, AM, Koeppe, RA, Meyer, CR: "Anatometabolic" tumor imaging: Fusion of FDG PET with CT or MRI to localization foci of increased activity. J Nucl Med, 34:1190-1197, 1993.

  62. Westera G; Reist HW; Buchegger F; Heusser CH; Hardman N; Pfeiffer A; Sharma HL; von Schulthess GK; Mach JP. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl Med Commun, 1991, 12:429-37.

Return to Top of References